Neurohormones and heart failure: The importance of aldosterone

International Journal of Clinical Practice

Volumn 60, Issue 7, 2006, Pages 835-846

  Odedra, K ^a   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aldosterone; Endothelial dysfunction; Fibrosis; Heart failure; Hypertrophy; Mineralocorticoid; Myocardium; Necrosis; Neurohormonal

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NEUROHORMONE; PLACEBO; SPIRONOLACTONE; VALSARTAN;

CLINICAL TRIAL; COUGHING; DISEASE COURSE; DISEASE MODEL; DRUG FATALITY; DRUG MECHANISM; ENDOTHELIUM LESION; GYNECOMASTIA; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; MASTALGIA; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASCULARIZATION;

ADAPTATION, PHYSIOLOGICAL; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMEGALY; CARDIOMYOPATHIES; ENDOTHELIUM, VASCULAR; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; NECROSIS; NEUROTRANSMITTER AGENTS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR RESISTANCE;

EID: 33745097437     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00996.x     Document Type: Review

References (59)

1. Department of Health, UK. The National Service Framework for Coronary Heart Disease: Winning the war on heart disease. Progress report 2004. http://www.dh.gov.uk.
2. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40.
3. Woods RL. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: A brief review. Clin Exp Pharmacol Physiol 2004; 31: 791-4.
4. Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 2005; 11: 30-8.
5. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-96.
6. Villarreal D, Freeman RH. 'Til death do us part: A case of failed affection. Cardiovasc Res 1995; 30: 27-30.
7. Tan LB, Williams SG, Goldspink DF. From CONSENSUS to CHARM -how do ACEI and ARB produce clinical benefits in CHF ? Int J Cardiol 2004; 94: 137-41.
8. Solomon SD, Wang D, Finn P et al. Effect of candesartan on cause-specific mortality in heart failure patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180-3.
9. Cohn JN, Tognoni G. A randomised trial of the angiotensin receptor blocker Valsartan in chronic heart failure. N Eng J Med 2001; 345: 1667-75.
10. McMurray JJV, Ostergren J, Svedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting inhibitors: The CHARM added trial. Lancet 2003; 362: 767-71.
11. Lechat P, Escolano S, Golmard JL et al. Prognostic value of bisoprolol-induced haemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997; 96: 2197-205.
12. Wiklund I, Waagstein F, Swedberg K et al. Quality of life on treatment with metoprolol in dilated cardiomyopathy: Results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardiovasc Drugs Ther 1996; 10: 361-8.
13. Tait JF, Simpson SAS, Grundy H. The effect of adrenal extract on mineral metabolism. Lancet 1952; 1: 1-21.
14. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-70.
15. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. For the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-6.
16. Duprez DA, DeBuyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-6.
17. Ramires FJ, Mansur A, Coelho O et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ishcaemic cardiomyopathy. Am J Cardiol 2000; 85: 1207-11.
18. Diez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res 1997; 35: 202-5.
19. Ferrario CM, Flack JM. Pathologic consequences of increased angiotensin II activity. Cardiovasc Drugs Ther 1996; 10: 511-8.
20. Struthers AD. Aldosterone escape during angiotensin converting enzyme inhibition therapy in chronic heart failure. J Card Fail 1996; 2: 54.
21. Duprez D, Buyzere M, Rietzschel ER et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327-34.
22. Struthers AD, MacDonald TM. Review of aldosterone and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-70.
23. Okubo S, Niimura F, Nishimura H et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997; 99: 855-60.
24. Schrier RW, Abraham WT. Hormones and haemodynamics in heart failure. N Engl J Med 2004; 341: 577-85.
25. Schrier RW, Better OS. Pathogenesis of ascites formation: Mechanism of impaired aldosterone escape in cirrhosis. Eur J Gastroenterol Hepatol 1991; 3: 721-9.
26. Hensen J, Abraham WT, Durr J, Schrier RW. Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention. Am J Nephrol 1991; 11: 441-6.
27. Slight S, Ganjam VK, Gomez-Sanchez CE et al. High affinity NAD+-dependent 11β -hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 1996; 28: 781 -7.
28. Millar CA, Ye P, Gray GA et al. Aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) gene expression in the normal and failing rat heart. Endocr Abstr 2003; 5: 234.
29. Takeda Y, Yoneda T, Demura M et al. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000; 36: 495.
30. Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-7.
31. Yoshimura M, Nakamura S, Ito T et al. Expression of aldosterone synthase gene in failing human heart: Quantitative analysis using modified real time polymerase chain reaction. J Clin Endocrinol Metab 2002; 87: 3936-40.
32. Hayashi M, Tsutamoto T, Wada A et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: Extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1375-82.
33. Rocha R, Stier CT Jr, Kifor I et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-8.
34. Oestreicher EM, Martinez-Vasquez D, Stone JR et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/ N G -nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003; 108: 2517-23.
35. Martinez DV, Rocha R, Matsumura M et al. Cardiac damage prevention by eplerenone: Comparison with low sodium diet or potassium loading. Hypertension 2002; 39: 614-8.
36. De Angelis N, Fiordaliso F, Latini R et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002; 34: 1655-65.
37. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283: H1802-10.
38. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-33.
39. Bauersachs J. Aldosterone antagonism in heart failure: Improvement of cardiac remodeling, endothelial dysfunction and platelet activation. Eur J Clin Invest 2004; 34: 649-52.
40. Fraccarollo D, Schäfer A, Hildemann S et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003; 42: 1666-73.
41. Hayashi M, Tsutamoto T, Wada A et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-65.
42. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000; 25: 299-306.
43. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997; 35: 138-47.
44. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001; 281: H647-54.
45. Suzuki G, Morita H, Mishima T et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-72.
46. Satoh M, Nakamura M, Saitoh H et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci 2002; 102: 381-6.
47. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227-32.
48. Ertl G. Aldosterone: From integrative physiology to cellular biology and back. Eur J Clin Invest 2004; 34: 653-5.
49. Duprez D, De Buyzere M, Rietzschel ER et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2: 327-34.
50. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: Role of endothelin-1. Am J Hypertens 2002; 15: 164-9.
51. Quaschning T, Ruschitzka F, Niggli B et al. Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 2001; 16: 2146-51.
52. Rajagopalan S, Duquaine D, King S et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-6.
53. Farquharson CAJ, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci 2002; 103: 425-31.
54. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
55. Bauersachs J, Heck M, Fraccarollo D et al. Addition of spironolactone to ACE inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol 2002; 39: 351-8.
56. Virdis A, Neves MF, Amiri F et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-10.
57. Pitt B, Zannad F, Remme W et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
58. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
59. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.